nach oben

nächster Artikel Ab interno canaloplasty for the treatment of gl...

Tipp

Long-term follow-up of half-fluence photodynamic therapy in acute central serous chorioretinopathy

Zeitschrift:: Spektrum der Augenheilkunde > Ausgabe 6/2018

Autoren:: MD Eva Smretschnig, MD Stefan Hagen, BSc Jutta Gamper, MD Ilse Krebs, MD Susanne Binder, MD Siamak Ansari-Shahrezaei

Wichtige Hinweise

Authors’ contributions

Design of the study (E. Smretschnig, S. Ansari-Shahrezaei), conduct of the study (E. Smretschnig, S. Hagen, J. Gamper, I. Krebs, S. Binder, S. Ansari-Shahrezaei), data collection and management (E. Smretschnig, S. Hagen), analysis (E. Smretschnig, J. Gamper, S. Ansari-Shahrezaei), interpretation (E. Smretschnig, S. Hagen, I. Krebs, S. Binder, S. Ansari-Shahrezaei), preparation (E.S, S. Ansari-Shahrezaei), review and final approval (E. Smretschnig, S. Hagen, I. Krebs, J. Gamper, S. Binder, S. Ansari-Shahrezaei)

Summary

Background

To evaluate the long-term results of indocyanine green angiography(ICGA)-guided verteporfin (Visudyne®, Novartis, Basel, Switzerland) photodynamic therapy (PDT) with half-fluence rate in the treatment of acute symptomatic central serous chorioretinopathy (CSC).

Material and methods

A retrospective review was performed of 12 patients with acute symptomatic CSC verified by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA), treated with ICGA-guided verteporfin (6 mg/m²)-PDT with half-fluence rate (25 J/cm²). The vision-related quality of life (VR QOL) 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) was completed by all patients and 82 controls.

Results

Best corrected visual acuity (BCVA) at baseline was 77.5 (±10; n = 12) according to the Early Treatment Diabetic Retinopathy Study (EDTRS) letter score and changed to 89 letters (±9.9; p = 0.0003) at long-term follow-up (83.8 ± 4.8 months after PDT). Baseline contrast sensitivity (CS) was 29.5 ± 4.5 Pelli–Robson letters and increased to 34.5 ± 4.5 letters at long term (p < 0.0006). Baseline central foveal thickness (CFT) was 419 μm and decreased to 242 µm at long term (p < 0.0001). The long-term vision-related quality of life of patients was similar to that of controls.

Conclusion

ICGA-guided half-fluence PDT with verteporfin results in excellent long-term visual improvement in BCVA and CS, a significant reduction of CFT, and high levels of VR QOL.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85–93. CrossRefPubMed

Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63:1–139.

Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46:160–3. CrossRefPubMed

Gass JD. Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed. Vol. 1. St.Louis: Mosby; 1997. pp. 52–70.

Han DP, Thompson HS, Folk JC. Differentiation between recently resolved optic neuritis and central serous retinopathy. Use of tests of visual function. Arch Ophthalmol. 1985;103:394–6. CrossRefPubMed

Ozkaya A, Alkin Z, Ozveren M, Yazici AT, Taskapili M. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study. Eye (Lond). 2016;30:1005–10. CrossRef

Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14:231–42. CrossRefPubMed

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65. CrossRefPubMed

Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005;112:2088–94. CrossRefPubMed

10.

Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. A randomized placebo-controlled trial. Retina. 2011;31:1378–86. CrossRefPubMed

11.

Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009;29:1155–61. CrossRefPubMed

12.

Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149:307–15. CrossRefPubMed

13.

Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32:2014–9. CrossRefPubMed

14.

Hagen S, Ansari-Shahrezaei S, Smretschnig E, Glittenberg C, Krebs I, Steiner I, et al. Effect of photodynamic therapy on short-wavelength fundus autofluorescence in eyes with acute central serous chorioretinopathy. Retina. 2015;35:223–30. CrossRefPubMed

15.

Hagen S, Ansari-Shahrezaei S, Smretschnig E, Glittenberg C, Krebs I, Graf A, et al. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251:1081–9. CrossRefPubMed

16.

Ferris FL III, Bailey I. Standardizing the measurement of visual acuity for clinical research studies: guidelines from the Eye Care Technology Forum. Ophthalmology. 1996;103:181–2. CrossRefPubMed

17.

Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–8. CrossRefPubMed

18.

Maaranen T, Mäntyjärvi M. Contrast sensitivity in patients recovered from central serous chorioretinopathy. Int Ophthalmol. 1999;23:31–5. CrossRef

19.

Rubin GS, Bandeen-Roche K, Huang GH, Muñoz B, Schein OD, Fried LP, et al. The association of multiple visual impairments with self report visual disability: SEE project. Invest Ophthalmol Vis Sci. 2001;42:64–72.

20.

Owsley C. Contrast sensitivity. Ophthalmol Clin North Am. 2003;16:171–7. CrossRefPubMed

21.

Rubin GS. Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci. 1988;2:169–77.

22.

Kyo T, Yuzawa M, Tochigi K, Yamaguchi T, Shimozuma K, Fukuhara S, et al. Assessment of the quality of life in patients with age-related macular degeneration 1 year after photodynamic therapy. Nippon Ganka Gakkai Zasshi. 2007;111:315–21. PubMed

23.

Mozaffarieh M, Krepler K, Heinzl H, Sacu S, Wedrich A. Visual function, quality of life and patient satisfaction after ophthalmic surgery: a comparative study. Ophthalmologica. 2004;218:26–30. CrossRefPubMed

24.

Türkcü FM, Sahin A, Bez Y, Yüksel H, Cinar Y, Kürşat, et al. Vision-related quality of life in patients with chronic central serous chorioretinopathy. Semin Ophthalmol. 2015;30:272–5. CrossRefPubMed

25.

Smretschnig E, Falkner-Radler CI, Binder S, Spörl J, Ristl R, Glittenberg C, et al. Vision-related quality of life and visual function after retinal detachment surgery. Retina. 2016;36:967–73. CrossRefPubMed

26.

Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010;51:744–51. CrossRefPubMed

27.

Okamoto F, Okamoto Y, Hiraoka T, Hiraoka T, Oshika T. Vision-related quality of life and visual function after retinal detachment surgery. Am J Ophthalmol. 2008;146:85–90. CrossRefPubMed

28.

Mason JO, Neimkin MG, Mason JO, Friedman DA, Feist RM, Thomley ML, et al. Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters. Retina. 2014;34:1055–61. CrossRefPubMed

29.

Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function following vitrectomy for proliferative diabetic retinopathy. Am J Ophthalmol. 2008;145:1031–6. CrossRefPubMed

30.

Fukuda S, Okamoto F, Yuasa M, Kunikata T, Okamoto Y, Hiraoka T, et al. Vision-related quality of life and visual function in patients undergoing vitrectomy, gas tamponade and cataract surgery for macular hole. J Ophthalmol. 2009;93:1595–9.

31.

Okamoto Y, Okamoto F, Hiraoka T, Oshika T. Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy. Jpn J Ophthalmol. 2014;58:369–74. CrossRefPubMed

32.

Aydin Kurna S, Altun A, Gencaga T, Akkaya S, Sengor T. Vision related quality of life in patients with keratoconus. J Ophthalmol. 2014; https://doi.org/10.1155/2014/694542. CrossRefPubMedPubMedCentral

33.

Zou H, Zhang X, Xu X, Liu H, Bai L, Xu X. Vision-related quality of life and self-rated satisfaction outcomes of rhegmatogenous retinal detachment surgery: three-year prospective study. PLoS ONE. 2011;6:e28597. CrossRefPubMedPubMedCentral

34.

Ghazi-Nouri SM, Tranos PG, Rubin GS, Adams ZC, Charteris DG. Visual function and quality of life following vitrectomy and epiretinal membrane peel surgery. Br J Ophthalmol. 2006;90:559–62. CrossRefPubMedPubMedCentral

35.

Tranos PG, Ghazi-Nouri SM, Rubin GS, Adams ZC, Charteris DG. Visual function and subjective perception of visual ability after macular hole surgery. Am J Ophthalmol. 2004;138:995–1002. CrossRefPubMed

36.

Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life. Am J Ophthalmol. 2009;147:869–74. CrossRefPubMed

37.

Lahousen T, Painold A, Luxenberger W, Schienle A, Kapfhammer HP, Ille R. Psychological factors associated with acute and chronic central serous chorioretinopathy. Nord J Psychiatry. 2016;70:24–30. CrossRefPubMed

38.

Lai TY, Wong RL, Chan WM. Long-term outcome of half-dose Verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2015;113:T81–T827.

39.

Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73. CrossRefPubMed

Titel: Long-term follow-up of half-fluence photodynamic therapy in acute central serous chorioretinopathy
Autoren:: MD Eva Smretschnig
MD Stefan Hagen
BSc Jutta Gamper
MD Ilse Krebs
MD Susanne Binder
MD Siamak Ansari-Shahrezaei
Publikationsdatum: 12.09.2018
DOI: https://doi.org/10.1007/s00717-018-0412-y
Verlag: Springer Vienna
Zeitschrift: Spektrum der Augenheilkunde
Ausgabe 6/2018
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Authors’ contributions

Summary

Background

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Erfolgreicher Nd:YAG-Laser-Eingriff als Therapie einer spontanen präretinalen Makulablutung bei einer 24-jährigen Patientin

Balder P. Gloor: Augenheilkunde von 1899 bis 1954, gelebt und gezeichnet. Der Nachlass von Dr. med. Arthur Gloor- Largiadèr in der Zentralbibliothek Solothurn

Ab interno canaloplasty for the treatment of glaucoma: a case series study

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Empfehlungen der Netzhautkommission der ÖOG zur Durchführung einer IVOM (intravitreale operative Medikamentenapplikation) 2017